Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 111 entries
View as:

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT03370172 Org: User:
Start: 03/31/18 End: 07/09/24 Due: 07/09/25

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Phase: N/A Priority: Normal
NCT ID: NCT03199794 Org: User:
Start: 12/14/16 End: 07/30/21 Due: 07/30/22

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

Phase: N/A Priority: Normal
NCT ID: NCT01687608 Org: User:
Start: 02/11/13 End: 01/17/30 Due: 01/17/31

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Phase: N/A Priority: Normal
NCT ID: NCT02525861 Org: User:
Start: 03/08/16 End: 07/29/20 Due: 07/29/21

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT00157040 Org: User:
Start: 06/07/02 End: 01/04/05 Due: 01/04/06

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00003056 Org: User:
Start: 04/01/97 End: 06/01/03 Due: 06/01/04

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02722304 Org: User:
Start: 11/02/16 End: 09/14/18 Due: 09/14/19

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Phase: N/A Priority: Normal
NCT ID: NCT03393975 Org: User:
Start: 10/13/17 End: 05/30/24 Due: 05/30/25

Osteoporosis and MRI Study in Hemophilia

Phase: N/A Priority: Normal
NCT ID: NCT01460147 Org: User:
Start: 10/30/11 End: 04/13/12 Due: 04/13/13

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT00243386 Org: User:
Start: 01/04/06 End: 06/16/10 Due: 06/16/11

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Phase: N/A Priority: Normal
NCT ID: NCT01485796 Org: User:
Start: 12/29/11 End: 01/01/13 Due: 01/01/14

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Phase: N/A Priority: Normal
NCT ID: NCT02556775 Org: User:
Start: 12/04/15 End: 12/17/19 Due: 12/17/20

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Phase: N/A Priority: Normal
NCT ID: NCT01913405 Org: User:
Start: 12/20/13 End: 09/23/16 Due: 09/23/17

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Phase: N/A Priority: Normal
NCT ID: NCT03879135 Org: User:
Start: 04/01/19 End: 01/30/25 Due: 01/30/26

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Phase: N/A Priority: Normal
NCT ID: NCT01410227 Org: User:
Start: 11/01/11 End: 02/01/14 Due: 02/01/15

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT04158934 Org: User:
Start: 07/09/20 End: 02/28/30 Due: 02/28/31

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03116347 Org: User:
Start: 05/30/17 End: 01/15/21 Due: 01/15/22

Aralast alpha1-proteinase Inhibitor Surveillance Study

Phase: N/A Priority: Normal
NCT ID: NCT00313144 Org: User:
Start: 06/09/06 End: 05/01/09 Due: 05/01/10

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

Phase: N/A Priority: Normal
NCT ID: NCT02190149 Org: User:
Start: 07/22/14 End: 03/29/16 Due: 03/29/17

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT02615691 Org: User:
Start: 11/12/15 End: 10/29/24 Due: 10/29/25

Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT00666406 Org: User:
Start: 03/31/08 End: 02/18/09 Due: 02/18/10

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02448810 Org: User:
Start: 06/15/15 End: 02/15/17 Due: 02/15/18

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Phase: N/A Priority: Normal
NCT ID: NCT00396006 Org: User:
Start: 10/27/06 End: 12/14/07 Due: 12/14/08

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT01178294 Org: User:
Start: 11/10/10 End: 10/09/13 Due: 10/09/14

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00157079 Org: User:
Start: 06/25/02 End: 12/16/03 Due: 12/16/04